Vericel (VCEL) investor relations material

Market trends and business performance

• Achieved record Q1 2026 revenue, with MACI revenue up 22% and Burn Care up 91% year-over-year.

• No slowdown in procedural volumes or patient flow, with record growth in key metrics through Q1 and into Q2.

• Guidance for the remainder of the year is set at high teens growth, reflecting prudence despite strong recent performance.

• Price increase of 9.5% implemented in May, with ongoing double-digit volume growth expected.

• Free cash flow reached $15M in Q1 2026, with cash and investments totaling ~$211M.

Pricing strategy and payer dynamics

• MACI is a unique, FDA-regulated combination device/biologic, not subject to CMS pricing, with price set by the company.

• Pricing is supported by regular research and is modest compared to other advanced cell therapies.

• Payers view MACI's cost as negligible relative to other therapies and procedures, with strong long-term outcomes data.

• Price increases are carefully managed to avoid payer pushback, with no anticipated changes to this approach.

• Sustained pricing power and low market penetration support continued strong growth.

Competitive landscape and market positioning

• No MACI-like competition expected in the foreseeable future; previous attempts have failed clinical endpoints.

• Alternatives like Agility, OCA, and OATS target different patient populations and are not expected to impact core business.

• Surgeons' treatment algorithms and patient profiles limit overlap with potential competitors.

• Regulatory and clinical barriers create a significant moat, with no biosimilar or 510(k) pathway for MACI-like products.

• Clinical trial requirements for new entrants are lengthy and challenging, reinforcing market leadership.